Patents by Inventor Toshiaki Wakabayashi

Toshiaki Wakabayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10995930
    Abstract: A rear light is a light disposed in a rear portion of a vehicle, and includes: a light source; a light-transmitting plate that guides incident light from the light source; and a dot portion that is disposed on the light-transmitting plate and reflects incident light to the outside of the vehicle with different reflection intensities depending on positions on the light-transmitting plate.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: May 4, 2021
    Assignee: MAZDA MOTOR CORPORATION
    Inventors: Naoki Yamamoto, Yoshiaki Nakaya, Toshiaki Wakabayashi, Takahiro Yamamoto
  • Publication number: 20200166193
    Abstract: A rear light is a light disposed in a rear portion of a vehicle, and includes: a light source; a light-transmitting plate that guides incident light from the light source; and a dot portion that is disposed on the light-transmitting plate and reflects incident light to the outside of the vehicle with different reflection intensities depending on positions on the light-transmitting plate.
    Type: Application
    Filed: November 14, 2019
    Publication date: May 28, 2020
    Applicant: MAZDA MOTOR CORPORATION
    Inventors: Naoki YAMAMOTO, Yoshiaki NAKAYA, Toshiaki WAKABAYASHI, Takahiro YAMAMOTO
  • Patent number: 8567854
    Abstract: An impact absorption member is provided behind a bumper face, a lower stiffener is provided below this member and projects forward to sweep a leg portion of an object hitting against a front potion of a vehicle, and headlamp units are provided at both side portions of the bumper face. A lamp housing of the headlamp unit is supported at a vehicle-body member located in back of the lamp housing, a load absorption portion provided on the inside of and rearward from an edge of the bumper face to absorb an impact load is provided integrally at the lamp housing, and a load transmission portion to transmit the impact load inputted to the bumper face to the load absorption portion is provided at the bumper face.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: October 29, 2013
    Assignee: Mazda Motor Corporation
    Inventors: Hiroyuki Nishi, Yasuyuki Emi, Tetsuo Nagata, Toshiaki Wakabayashi, Kazuma Kondo, Toshio Sakamoto
  • Patent number: 8240235
    Abstract: The present invention provides a method of minimal quantity lubrication cutting and grinding that can improve cutting and grinding properties and extend the life of tools. The minimal quantity lubrication cutting and grinding method of the present invention comprises supplying a compressed fluid containing 0.1 to 15 percent by volume of oxygen together with a cutting and grinding oil (particularly preferably an oil composition comprising an ester) to processing spots of a workpiece.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: August 14, 2012
    Assignee: Nippon Oil Corporation
    Inventors: Satoshi Suda, Masahiro Hata, Masanori Ibi, Ichiro Inasaki, Toshiaki Wakabayashi
  • Publication number: 20120049547
    Abstract: An impact absorption member is provided behind a bumper face, a lower stiffener is provided below this member and projects forward to sweep a leg portion of an object hitting against a front potion of a vehicle, and headlamp units are provided at both side portions of the bumper face. A lamp housing of the headlamp unit is supported at a vehicle-body member located in back of the lamp housing, a load absorption portion provided on the inside of and rearward from an edge of the bumper face to absorb an impact load is provided integrally at the lamp housing, and a load transmission portion to transmit the impact load inputted to the bumper face to the load absorption portion is provided at the bumper face.
    Type: Application
    Filed: August 18, 2011
    Publication date: March 1, 2012
    Applicant: MAZDA MOTOR CORPORATION
    Inventors: Hiroyuki NISHI, Yasuyuki EMI, Tetsuo NAGATA, Toshiaki WAKABAYASHI, Kazuma KONDO, Toshio SAKAMOTO
  • Patent number: 7834049
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: November 16, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20100267754
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Application
    Filed: June 10, 2010
    Publication date: October 21, 2010
    Inventors: Toshiaki WAKABAYASHI, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20100011923
    Abstract: The present invention provides a method of minimal quantity lubrication cutting and grinding that can improve cutting and grinding properties and extend the life of tools. The minimal quantity lubrication cutting and grinding method of the present invention comprises supplying a compressed fluid containing 0.1 to 15 percent by volume of oxygen together with a cutting and grinding oil (particularly preferably an oil composition comprising an ester) to processing spots of a workpiece.
    Type: Application
    Filed: July 27, 2007
    Publication date: January 21, 2010
    Applicant: NIPPON OIL CORPORATION
    Inventors: Satoshi Suda, Masahiro Hata, Masanori Ibi, Ichiro Inasaki, Toshiaki Wakabayashi
  • Publication number: 20090269352
    Abstract: The present invention provides a composition and a kit for treating tumors, which permits a sulfonamide-containing heterocyclic compound to exhibit its angiogenesis inhibitory activity and antitumor activity more effectively. According to the present invention, the sulfonamide-containing heterocyclic compound can be used in treating cancers more effectively by combination with a VEGF inhibitor/FGF inhibitor.
    Type: Application
    Filed: July 6, 2009
    Publication date: October 29, 2009
    Inventors: Toshiaki WAKABAYASHI, Naoto Ono, Taro Semba, Toru Haneda
  • Publication number: 20090047278
    Abstract: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer, comprising a sulfonamide compound in combination with a substance having an EGF inhibitory activity.
    Type: Application
    Filed: February 28, 2006
    Publication date: February 19, 2009
    Applicant: Eisai R & D Management Co., Ltd.
    Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba, Toshiaki Wakabayashi
  • Patent number: 7122318
    Abstract: The present invention provides a system for testing the influence of a drug on integrin expression, which comprises measuring an integrin expression level in platelets of an individual to which the drug is administered and, based on the measured expression amount, determining what effect the drug has on integrin expression in cells other than platelets.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: October 17, 2006
    Assignee: Eisai Co., Ltd.
    Inventors: Naoto Ono, Taro Senba, Naoko Hata, Yasuhiro Funahashi, Toshiaki Wakabayashi
  • Publication number: 20050176712
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.
    Type: Application
    Filed: April 4, 2005
    Publication date: August 11, 2005
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Publication number: 20050119303
    Abstract: The present invention provides a composition and a kit for treating tumors, which permits a sulfonamide-containing heterocyclic compound to exhibit its angiogenesis inhibitory activity and antitumor activity more effectively. According to the present invention, the sulfonamide-containing heterocyclic compound can be used in treating cancers more effectively by combination with a VEGF inhibitor/FGF inhibitor.
    Type: Application
    Filed: March 4, 2003
    Publication date: June 2, 2005
    Applicant: EISAI CO., LTD
    Inventors: Toshiaki Wakabayashi, Naoto Ono, Taro Semba, Toru Haneda
  • Patent number: 6858569
    Abstract: Cutting or grinding oil compositions which are suitable for use in a minimal quantity lubrication system in which a minimal quantity of an oil is supplied to the spot to be cut or ground of a work, together with air are reduced in stickiness and improved in lubricity.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: February 22, 2005
    Assignee: Nippon Mitsubishi Oil Corporation
    Inventors: Hideo Yokota, Noboru Aota, Yoshitaka Natsume, Masanori Ibi, Minoru Okajima, Ichiro Inezaki, Toshiaki Wakabayashi, Satoshi Suda
  • Patent number: 6787534
    Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: September 7, 2004
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Naoko Tsukahara, Takashi Owa
  • Publication number: 20040132783
    Abstract: A method for testing influence of a drug on integrin expression, which comprises the step of measuring an integrin expression amount in platelets of a patient to which the drug is administered and the step of determining influence of the drug on integrin expression in cells other than platelets based on the measured expression amount.
    Type: Application
    Filed: January 20, 2004
    Publication date: July 8, 2004
    Inventors: Naoto Ono, Taro Senba, Naoko Hata, Yasuhiro Funahashi, Toshiaki Wakabayashi
  • Publication number: 20040018192
    Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 29, 2004
    Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
  • Patent number: 6673787
    Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 6, 2004
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara
  • Patent number: 6645996
    Abstract: The present invention provides a novel bioactive substance having an antiangiogenic effect. The chemical compound represented by the formula (1) (wherein, R1 represents hydrogen atom, aldehyde group or a lower acyl group, R2 and R3 are the same as or different from each other and represent hydrogen atom or a lower alkoxy group or are combined to represent oxygen atom, R4 represents a lower alkyl group and R5 represents hydrogen atom or a lower alkyl group, provided that compounds in which R1 is aldehyde group, R2 and R3are different from each other and are hydrogen atom or methoxy group, R4 is ethyl group and R5 is hydrogen atom are excluded), a salt thereof or a hydrate thereof was isolated from the culture broth of genus Streptomyces and the structure thereof was analyzed.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: November 11, 2003
    Assignee: Mercian Corporation and Eisai Co., Ltd.
    Inventors: Toshiaki Wakabayashi, Rena Kawase, Nobuaki Naruse, Masanori Fujita, Tomohiro Sameshima, Yoshio Watanabe, Kazuyuki Dobashi, Yasuhiro Funahashi, Taro Semba
  • Patent number: 6638964
    Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof: In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: October 28, 2003
    Assignee: Eisai Co., Ltd.
    Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara